Geron (GERN) may produce "financial bonanza" proclaims Eli Lilly chairman emeritus:
"At a recent New York scientific meeting, the chairman emeritus of Eli Lilly, Randall Tobias, tantalized attendees with 21st Century visions that until recently would have been the province of science fiction writers.
The day will come, Tobias said, when we regard all surgeries, except trauma, as failures of the pharmaceutical industry. The end of surgery? Now that is a vision we can all look forward to.
Tobias likened medicine today to where the aerospace industry was at the time of Charles Lindbergh's historic trans-Atlantic flight in 1927. But the pace of developments in the life sciences, he predicted, will rapidly catapult biotechnology to the equivalent of landing a human on the moon.
Tobias' comments were reported by Laurie Garrett of Newsday. Her article summarized biotech's great promise, a time in the next century when preventive care will be so sophisticated as to eliminate many of the diseases that afflict humankind today.
Many biotech companies are surging ahead with scientific developments that not only boggle the mind, but may produce financial bonanzas for those companies that can leverage their science into commercial products.
Among the most exciting:
Geron Corp. (Nasdaq:GERN - news) is focused on the relationship between telomere erosion, the aging process and disease formation. Geron is pursuing the discovery of therapies that activate telomerase in normal cells, to postpone disease, and inhibit telomerase in cancer cells to re-mortalize tumors."
See: biz.yahoo.com
Regards,
Jake Blackmerlin |
